Acid-reducing drugs, also called proton pump inhibitors (PPI), are one of the most successful drug classes ever launched, projected to earn as much as $3.26 billion in profits in the year 2026. “Twenty-five years after their introduction into clinical practice, PPIs remain the mainstay of the treatment of acid-related diseases,” research published in the journal…